ICCM News and Press, IceCure Medical Ltd. From 02/09/23

IceCure Medical ( NASDAQ: ICCM ) announced preliminary unaudited revenues of $3.1M in 2022, compared to $4.1M a year earlier,  due to decreased revenue recognition of about $0.6M from the distribution agreement with Terumo and a decrease of sales in most territories by 25%. Analy...

IceCure Medical Announces Preliminary Unaudited 2022 Year-End Financial Results & Recent Operational Highlights IceCure Medical Announces Preliminary Unaudited 2022 Year-End Financial Results & Recent Operational Highlights PR Newswire - Significant regulatory an...

IceCure's ProSense Featured in Breast Session at the Society of Interventional Oncology's Annual Scientific Meeting in Washington, D.C. PR Newswire Panel discussion included doctors currently using the ProSense cryoablation system Live ProSense demonstrations c...

IceCure's ProSense Presented in Hands-On Training Course at The American Society of Breast Surgeons Breast Follows Ultrasound Course PR Newswire Professional training courses are well-timed following IceCure's FDA filing for marketing authorization of ProSense with breakthro...

U.S. Patent Office Grants Notice of Allowance to IceCure for Novel Cryogenic Pump for Next-Generation Cryoablation Systems PR Newswire Patent has also been granted or allowed in major markets, including the European Union and Japan Cryogenic pump potentiall...

IceCure Medical ( NASDAQ: ICCM ) said it received a Notice of Allowance from the Japan Patent Office (JPO) for its novel cryogenic pump for cryoablation systems. The patent titled 'Cryogen Pump' will be in effect until 2041. A patent for this invention has alrea...

IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogenic Pump for its Next-Generation Cryoablation Systems PR Newswire Innovating as a global leader in cryoablation technologies, with 29 patents issued and allowed Cryogenic pump enables multip...

IceCure Medical ( NASDAQ: ICCM ) said on Tuesday it was publicly offering 8.79M shares priced at-the-market to the public of $1.65 per share. ( ICCM ) has risen ~9% before the bell. The gross proceeds, which is about $14.5M, will be used to fund the development of...

IceCure Medical Ltd. Announces Closing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules PR Newswire CAESAREA, Israel , Dec. 23, 2022 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer o...

IceCure Medical Ltd. Announces Pricing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules PR Newswire CAESAREA, Israel , Dec. 21, 2022 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer o...